New Cervical Cancer Screening Guidelines: Was the Annual Pap Too Much of a Good Thing?

MARGARET M. FIELDS, MSN, ACNP-BC, AOCNP®

Fifty years ago in the United States, the leading cause of cancer death among women was cervical carcinoma. With the advent of the Papanicolaou (Pap) test in 1945, mortality from this malignancy declined more than 70% (Datta et al., 2008; Spitzer, 2007). An annual Pap smear was the recommended guideline for many years. New cervical cancer guidelines were released by the United States Preventative Services Task Force (USPSTF) on March 14, 2012.

WHAT ARE THE NEW GUIDELINES?

The following points summarize the new USPSTF cervical cancer screening guidelines:

- Begin screening at age 21 with use of cytology alone every 3 years from ages 21–29. No screening prior to age 21 regardless of age of coitarche.
- Patients with atypical squamous cells of undetermined significance (ASCUS) on cytology with negative human papillomavirus (HPV) status should be managed the same way as patients with negative cytology.
- Women ages 30–65 should be screened every 5 years with co-testing (cytology and HPV) or every 3 years with cytology alone if co-testing is not available.
- Women over age 65 can discontinue screening. Once discontinued, screening should not resume even if a woman has a new sexual partner.
- No screening is needed after hysterectomy if there is no prior history of cervical intraepithelial neoplasia grade 2 (CIN2) or higher grade lesion.
- Following spontaneous regression or treatment, women with a history of CIN2 or higher grade lesion should continue screening, even if this extends beyond age 65 (Schwaiger, Aruda, LaCoursiere, & Rubin, 2012).

WHAT IS DIFFERENT FROM PAST GUIDELINES?

The previous guidelines initiated screening 3 years after beginning sexual activity but no later than age 21. Women younger than 30 were recommended to have a Pap test every 2 years. For women 30 or older, the recommendation was every 3 years if they had had 3 consecutive negative Pap tests. These guidelines issued in 2009 recommended less frequent screening than the prior guidelines from 2003, which recommended women younger than age 30 have an annual exam (Solomon, Breen, & McNeel, 2008; Sawaya, 2009).

WHY THE CHANGE?

In order to understand why the previous screening guidelines, which
resulted in such a dramatic decrease in mortality, have now changed, it is essential to understand how the knowledge of cervical carcinogenesis has progressed through the years.

Human papillomavirus is the primary causative agent of cervical carcinoma. Persistent infection is necessary for cancer to develop; this is a process that evolves over decades from preinvasive intraepithelial neoplasia to invasive cancer (Denny, 2012). Human papillomavirus is extremely prevalent; the lifetime risk of infection is 80% (Veldhuijzen, Snijders, Reiss, Meijer, & van de Wijgert, 2010). Current estimates are that 50% to 80% of young sexually active women will contract HPV infection within 24 to 36 months of coitarche (Datata et al., 2008). The prevalence of HPV infection in the US is 40% among sexually active women ages 14–19, and 49.3% among sexually active women 20–24 years old. The good news is that 90% of women have been found to clear the infection without intervention within 2 years. Human papillomavirus persistence, which is necessary for the development of cervical cancer, affects only a small percentage of women who acquire HPV (Veldhuijzen et al., 2010; Widdice & Moscicki, 2008).

The majority of cervical cancers are related to two specific strains of HPV. HPV 16 accounts for 51% of cervical cancers and HPV 18 for 16%. Additional strains of HPV that are related to cervical cancer include HPV 35 (8.7%) and HPV 45 (7.4%; Clifford, Smith, Plummer, Munoz, & Franceschi, 2003). This equates to a stronger correlation between high-risk HPV and cervical cancer than that between smoking status and lung cancer (Denny, 2012).

Young women are particularly prone to acquiring HPV infection due to the anatomy of the immature cervix. The adult cervix contains protective squamous epithelium, whereas the immature cervix contains columnar epithelium. During the adolescent period, this tissue undergoes metaplasia and transforms to squamous epithelium. During metaplasia, HPV has easier access to the basal cell layer, the site of rapid replication and differentiation (Hwang et al., 2012; Moscicki & Cox, 2010; Moscicki, 2007). Despite this susceptibility to HPV infection, 90% of young women are able to clear the infection without intervention and hence avoid development of invasive cervical cancer (Moore et al., 2010; Moscicki, 2007; Moscicki & Cox, 2010).

Women ages 15 through 19 have a very low incidence of invasive cervical cancer, at a rate of 0.1/100,000 (Moscicki & Cox, 2010). This rate has remained unchanged for 4 decades despite increased screening coverage (Castle & Carreon, 2010). Therefore, deferring the onset of cervical screening until age 21 is unlikely to have a significant impact on the overall incidence of cervical cancer. The benefit of delayed onset of screening is the reduction in the number of colposcopies and biopsies for young women with transient HPV changes that will likely resolve on their own in 6 to 36 months (Schwaiger et al., 2012; Moscicki & Cox, 2010). Not only is emotional and physical discomfort avoided, but there is a decrease in health-care costs seen with the elimination of unnecessary colposcopies and biopsies as well. Finally, there are long-term consequences of treatment of dysplasia with cryotherapy or the loop electrosurgical excision procedure (LEEP). These include cervical stenosis, incompetent cervix, increased risk of premature delivery, low birth weight, and premature rupture of membranes (Moscicki & Cox, 2010; Krygiou et al., 2006).

EXCEPTIONS TO THE GUIDELINES

It is important to keep in mind that the new cervical cancer screening guidelines do not apply to women who are immunosuppressed, including patients with HIV or immunosuppression related to organ transplantation. Also excluded from these screening guidelines are women with a history of cervical cancer or in utero exposure to diethylstilbestrol (DES). Additional risk factors for the development of invasive cervical cancer to bear in mind include smoking and having a history of multiple sexual partners (Hwang et al., 2012; Schwaiger et al., 2012).

Surveillance, Epidemiology, and End Results (SEER) data demonstrate that cervical cancer is not a disease of youth and HPV acquisition, but rather one that occurs in the middle-aged to
older female and is related to the persistence of HPV (National Cancer Institute, 2012); see Table 1. Based on what we have learned through the years about the cause of cervical cancer and the timeline for development from intraepithelial neoplasia to invasive cancer, the new guidelines are medically sound and should continue to adequately protect women from invasive disease.

PREVENTION

In recent years, we have learned more about the cause and development of invasive cervical cancer and are now poised to move from the practice of secondary prevention to primary prevention. In the past decade, vaccines have been developed to target high-risk strains of HPV. A bivalent vaccine (Cervarix [GlaxoSmithKline, 2009]) is targeted toward HPV 16 and 18. A quadrivalent vaccine (Gardasil [Merck, 2006]) is targeted to HPV 6, 11, 16, and 18. Both are commercially available and approved for males and females ages 9 through 26. These vaccines are able to decrease the risk of cervical and other HPV-related cancers (Denny, 2012; Malagón et al., 2012).

CONCLUSIONS

The focus of the well-woman examination may now shift from that of the annual Pap test to cancer screening, assessment of cardiovascular risk factors, and evaluation of thyroid health. The clinician will be better able to encourage fitness and promote overall health. As many young women do not regularly see a primary care physician, the annual well-woman visit may be their only healthcare contact. Having more time to devote to issues of overall health and well-being will help build stronger relationships between clinicians and patients, resulting in increased mutual benefit.

DISCLOSURE

The author has no conflicts of interest to disclose.

REFERENCES

Castle, P. E., & Carreon, J. D. (2010). Practice improvement in cervical screening and management (PICSM): Symposium on management of cervical abnormalities in adolescents and young women. Journal of Lower Genital Tract Disease, 14, 238–340. http://dx.doi.org/10.1097/LGT.0b013e3181d95ad6
Clifford, G. M., Smith, J. S., Plummer, M., Munoz, N., & Franceschi, S. (2003). Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. British Journal of Cancer, 88, 63–73. http://dx.doi.org/10.1038/sj.bjc.6600688
Datta, S. D., Koutshky, L. A., Ratelle, S., Unger, E. R., Shlay, J., McClain, R.,...Weinstock, H. (2008). Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States 2003–2005. Annals of Internal Medicine, 148, 493–497.
Denny, L. (2012). Cervical cancer prevention: New opportunities for primary and secondary prevention in the 21st century. International Journal of Gynecology and Obstetrics, 119 (suppl 1), S80–S84.
GlaxoSmithKline. (2009). Cervarix package insert. Retrieved from http://us.gsk.com/products/assets/us_cervarix.pdf
Hwang, L. Y., Ma, Y., Shiboski, S. C., Farhat, S., Jonte, J., & Moscicki, B. A. (2012). Active squamous metaplasia of the cervical epithelium is associated with subsequent acquisition of human papilloma virus 16 infection among healthy young women. Journal of Infectious Diseases, 206, 504–511. http://dx.doi.org/10.1093/infdis/jis398
Krygiou, M., Koliopoulos, G., Martin-Hirsch, P., Arbyn, M., Prendiville, W., & Paraskevaidis, E. (2006). Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: Systematic review and meta-analysis. Lancet, 367, 489–498. http://dx.doi.org/10.1016/S0140-6736(06)68181-6
Malagón, T., Drolet, M., Boily, M. E., Franco, E. L., Jit, M., Brisson, J., & Brisson, M. (2012). Cross-protective efficacy of two human papillomavirus vaccines: A systematic review and meta-analysis. Lancet Infectious Diseases, 12, 781-789. http://dx.doi.org/10.1016/S1473-3099(12)70187-1
Merck. (2006). Gardasil package insert. Retrieved from http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf
Moore, G., Fetterman, B., Cox, J. T., Poitrás, N., Lorey, T., Kinney, W., & Castle, P. E., (2010). Lessons from practice: Risk of CIN 3 or cancer associated with an LSIL or HPV-positive ASC-US screening result in women aged 21 to 24. Journal of Lower Genital Tract Disease, 14, 97–102. http://dx.doi.org/10.1007/LGT.0b013e3181b8b024
Moscicki, A. B. (2007). HPV infections in adolescents. Disease Markers, 23, 229–234.
Moscicki, A. B., & Cox, J. T. (2010). Practice improvement in cervical screening and management (PICS): Symposium on management of cervical abnormalities in adolescents and young women. *Journal of Lower Genital Tract Disease, 14*, 73–80. http://dx.doi.org/10.1097/LGT.0b013e3181cec411

National Cancer Institute. (2012). SEER Stat Fact Sheets: Cervix uteri. Retrieved from http://seer.cancer.gov/statfacts/html/cervix.html

Sawaya, G. (2009). Cervical cancer screening: New guidelines and the benefits between benefits and harms. *New England Journal of Medicine, 361*, 2503–2505. http://dx.doi.org/10.1056/NEJMp0911380

Schwaiger, C., Aruda, M., LaCoursiere, S., & Rubin, R. (2012). Current guidelines for cervical cancer screening. *Journal of the American Academy of Nurse Practitioners, 24*, 417–424. http://dx.doi.org/10.1111/j.1745-7599.2012.00704.x

Solomon, D., Breen, N., & McNeel, T. (2008). Cervical cancer screening rates in the United States and the potential impact of implementation of screening guidelines. *CA: A Cancer Journal for Clinicians, 57*, 105–111. http://dx.doi.org/10.3322/canjclin.57.2.105

Spitzer, M. (2007). Screening and management of women and girls with human papillomavirus infection. *Gynecologic Oncology, 107*, S14–S18. http://dx.doi.org/10.1016/j.ygyno.2007.07.069

Velhuijzen, N. J., Snijders, P. J., Reiss, P., Meijer, C. J., & van de Wijgert, J. H. (2010). Factors affecting transmission of mucosal human papillomavirus. *Lancet Infectious Disease, 10*, 862–874. http://dx.doi.org/10.1016/S1473-3099(10)70190-0

Widdice, L. E., & Moscicki, A. B. (2008). Updated guidelines for Papanicolaou tests, colposcopy, and human papillomavirus testing in adolescents. *Journal of Adolescent Health, 43*, S41–S51. http://dx.doi.org/10.1016/j.jadohealth.2008.04.007